Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tore Saxne

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Arthritis and Rheumatism|November 30, 2006
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximabKlaus Bendtzen, Pierre Geborek, Morten Svenson, et al.
The Journal of Rheumatology|April 3, 2016
Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern SwedenJon Thorkell Einarsson, Pierre Geborek, Tore Saxne, et al.
Rheumatology (Oxford, England)|January 12, 2018
Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosisRoger Hesselstrand, Johanna Nagel, Tore Saxne, et al.
Arthritis Research & Therapy|July 28, 2006
Predictors of infusion reactions during infliximab treatment in patients with arthritisMeliha C Kapetanovic, Lotta Larsson, Lennart Truedsson, et al.
Arthritis and Rheumatism|August 12, 2011
Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitorsMeliha Crnkic Kapetanovic, Carmen Roseman, Göran Jönsson, et al.
BMC Rheumatology|March 20, 2019
Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatmentPer Nived, Tore Saxne, Pierre Geborek, et al.
Ugeskrift for Laeger|February 7, 2007
[Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication]Klaus Bendtzen, Pierre Geborek, Morten Svenson, et al.
Vaccine|January 14, 2017
Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccineMeliha C Kapetanovic, Johanna Nagel, Inger Nordström, et al.
Arthritis Care & Research|September 5, 2014
Development of functional impairment and disability in rheumatoid arthritis patients followed for 20 years: relation to disease activity, joint damage, and comorbidityMeliha C Kapetanovic, Elisabet Lindqvist, Jan-Åke Nilsson, et al.
Arthritis Research & Therapy|January 4, 2014
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritisMeliha C Kapetanovic, Lars-Erik Kristensen, Tore Saxne, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Arthritis and Rheumatism|November 30, 2006
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximabKlaus Bendtzen, Pierre Geborek, Morten Svenson, et al.
The Journal of Rheumatology|April 3, 2016
Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern SwedenJon Thorkell Einarsson, Pierre Geborek, Tore Saxne, et al.
Rheumatology (Oxford, England)|January 12, 2018
Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosisRoger Hesselstrand, Johanna Nagel, Tore Saxne, et al.
Arthritis Research & Therapy|July 28, 2006
Predictors of infusion reactions during infliximab treatment in patients with arthritisMeliha C Kapetanovic, Lotta Larsson, Lennart Truedsson, et al.
Arthritis and Rheumatism|August 12, 2011
Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitorsMeliha Crnkic Kapetanovic, Carmen Roseman, Göran Jönsson, et al.
BMC Rheumatology|March 20, 2019
Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatmentPer Nived, Tore Saxne, Pierre Geborek, et al.
Ugeskrift for Laeger|February 7, 2007
[Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication]Klaus Bendtzen, Pierre Geborek, Morten Svenson, et al.
Vaccine|January 14, 2017
Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccineMeliha C Kapetanovic, Johanna Nagel, Inger Nordström, et al.
Arthritis Care & Research|September 5, 2014
Development of functional impairment and disability in rheumatoid arthritis patients followed for 20 years: relation to disease activity, joint damage, and comorbidityMeliha C Kapetanovic, Elisabet Lindqvist, Jan-Åke Nilsson, et al.
Arthritis Research & Therapy|January 4, 2014
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritisMeliha C Kapetanovic, Lars-Erik Kristensen, Tore Saxne, et al.
Pageof 9